BRD2 and neoplasm: Common chemotherapeutic agents used in NAT, such as anthracyclines, taxanes, anti‐HER2 monoclonal antibodies trastuzumab and pertuzumab, can directly induce immunostimulatory effects of tumor cell killing through DC activation.12